Results 101 to 110 of about 724,283 (165)

Immunomodulators and advanced therapies for maintenance of remission in Crohn’s disease: systematic review and network meta-analysis

Therapeutic Advances in Gastroenterology
Background: With the range of options available for the treatment of Crohn’s disease, therapy selection can be challenging in clinical practice. Comparative efficacy data are needed to clarify the relative position of the increasingly complex portfolio ...
Vassiliki Sinopoulou, Morris Gordon, Shiyao Liu, Daniel Arruda Navarro Albuquerque, Aderonke Ajiboye, Sudheer Kumar Vuyyuru, Shellie Jane Radford, Gordon William Moran   +7 more
doaj   +1 more source

CT-P13 biosimilar is non-inferior to infliximab [PDF]

Nature Reviews Gastroenterology & Hepatology, 2019
openaire   +2 more sources

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

BMC Rheumatology
Background CT-P13 SC, a new subcutaneous (SC) formulation of biosimilar infliximab (IFX), was approved by the European Medicines Agency in 2020 for the treatment of radiographic axial spondyloarthritis (axSpA) in adult patients.
Xenofon Baraliakos, Ye Eun Lee, Soyeon Park, Young Nam Lee, Isabel Truman, Molly Edwards, Emily Quiñones, Raj Sengupta   +7 more
doaj   +1 more source

Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience

, 2018
Objectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim to assess the efficacy and safety of switching from originator infliximab
Gracie, DJ, David J. Gracie, Ratnakumaran, R, Selinger, CP, Anthony O'Connor, Clark, T, Bourner, L, O'Connor, A, Natalie To, Carey, N, To, N, Hamlin, PJ, Lynsey Bourner, P. John Hamlin, Leigh, K, Nicola Carey, Christian P. Selinger, Tanya Clark, Ford, AC, Katherine Leigh, Alexander C. Ford, Raguprakash Ratnakumaran   +21 more
core   +1 more source

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. [PDF]

BMC Health Serv Res, 2022
Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-Biroulet L, Sreedhar S, Potter J, Jang M.   +7 more
europepmc   +1 more source

CT-P13: a safe and effective treatment for IBD [PDF]

Nature Reviews Gastroenterology & Hepatology, 2016
openaire   +1 more source

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis. [PDF]

J Clin Med, 2021
Lee SS, Kim TH, Park W, Song YW, Suh CH, Kim SK, Yoo DH.   +6 more
europepmc   +1 more source

Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease [PDF]

Gastroenterology, 2017
Fiorino G, Ruiz-Aguello MB, Maguregui A, Nagore D, Radice S, Gilardi D, Correale C, Allocca M, Furfaro F, Alfieri M, Martinez A, Danese S   +11 more
openaire   +3 more sources

Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. [PDF]

J Gastroenterol Hepatol, 2021
Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T.   +5 more
europepmc   +1 more source

Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). [PDF]

Rheumatol Adv Pract, 2021
Taylor PC, Christensen R, Moosavi S, Selema P, Guilatco R, Fowler H, Mueller M, Liau KF, Haraoui B.   +8 more
europepmc   +1 more source